Leerink Partners

We are pleased to serve as financial advisor to Surgery Partners on its Sale to HealthSpan Partners for ~$5.7 Billion. Learn more about us and see all of our transactions online at https://lnkd.in/eBA_y88n

We are pleased to announce that Josh Ezrin, Tom McCaffrey, and Brian Furbush have joined our Institutional Equities team. Click here to view the full press release: https://lnkd.in/e3JfztBC Learn more about Leerink Partners: https://leerink.com/

Senior Research Analyst David Risinger recently joined Barron's 2026 Healthcare Roundtable to discuss the accelerating momentum in biotech, the growing role of AI in drug discovery, and the opportunities shaping the future of healthcare investing. Read the full article here: https://lnkd.in/eTXvxbFv

We've been joined by an outstanding group of industry leaders on the Perspectives by the Leerink Center for Pharmacoeconomics podcast to discuss recent developments and industry trends around the incentives for and impacts of biopharmaceutical innovation: 🎙️ Tomas Philipson, PhD (Former Acting Chairman, White House Council of Economic Advisers) told us about a new insurance for clinical trial failure and how novel financial mechanisms could potentially reshape risk-taking and investment in drug development. 🎙️ John O'Brien, PharmD, MPH (Former Trump Drug Pricing Advisor & Current President & CEO, National Pharmaceutical Council) joined us to discuss the evolving drug policy landscape and what to watch out for in 2026. 🎙️ Inma Hernandez, PharmD, MPH (Senior Advisor for Drugs Prices, Centers for Medicare and Medicaid Services) gave us a drug pricing 101 including an overview of the drug pricing regulatory dynamics for branded drugs in the US. Whether you're interested in drug pricing, health economics, biotech investing, or policy, there's something here for you. Check out the full episodes here: https://lnkd.in/g2ZVXjTr The Leerink Center for Pharmacoeconomics is a division of MEDACorp which is an affiliate of Leerink Partners.

Should biotech companies and investors use health economic modeling? In this episode of Perspectives by the Leerink Center for Pharmacoeconomics, Melanie Whittington sits down with Peter Kolchinsky of RA Capital Management to discuss if the U.S. market-based approach to pricing novel prescription medicines could result in paying more than they are worth and if companies and company builders should use health economic modeling to support their value propositions. Listen to the full episode now: Apple Podcasts: https://lnkd.in/enD4ZyqQ Spotify: https://lnkd.in/eFGFxfwZ The Leerink Center for Pharmacoeconomics is a division of MEDACorp which is an affiliate of Leerink Partners.

Should development-stage biotechs be thinking about health economics before launch? In our latest episode of Perspectives by the Leerink Center for Pharmacoeconomics, Melanie Whittington sits down with Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research, to talk about the relevance of health economics and outcomes research (HEOR) for biotech founders, executives, and investors. Clinical evidence shows if your drug works. HEOR evidence shows if your drug is worth it. The discussion gets into: -HEOR activities biotech companies can do before Phase III -Questions investors can ask management teams to gauge commercial opportunity -Use cases of HEOR for biotech executives and investors Watch the full episode here: https://lnkd.in/ekJJCwPz Apple Podcasts: https://lnkd.in/ehbStDpE Spotify: https://lnkd.in/eck4U2pT The Leerink Center for Pharmacoeconomics is a division of MEDACorp which is an affiliate of Leerink Partners.